BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
Phase Ib: Dose exploration: To assess the safety, tolerability, and determine the recommended
Phase 2 dose (RP2D) of BC3402 in combination with durvalumab in subjects with advanced
hepatocellular carcinoma (HCC) Phase II: Dose Expansion: To assess the antitumor activity of
BC3402 in combination with durvalumab in subjects with advanced HCC.